Physician profile
Bernard Allan Silverman
NPI 1033192836
$62,996.01
in general payments reported to CMS, 2019-2025
15 companies · $59K in 2025
The $59K reported for 2025 was more than what 96% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,573 · 2020: $336 · 2021: $279 · 2022: $124 · 2023: $197 · 2024: $116 · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $58K · Food and Beverage: $1,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,403.20 |
| Food and Beverage | $1,280.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $58,403.20 | 2025 | |
| Astrazeneca Uk Limited | $1,929.80 | 2019 | |
| Genzyme Corporation | $1,127.03 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $289.77 | 2020-2023 | Dupixent |
| Glaxosmithkline, LLC. | $283.78 | 2021-2025 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $222.11 | 2019-2023 | Airsupra, Tezspire |
| Genentech USA, INC. | $163.45 | 2019-2025 | Xolair |
| Amgen INC. | $156.65 | 2020-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $138.82 | 2019-2025 | |
| Alk-Abello, INC | $111.26 | 2019 | |
| Merck Sharp & Dohme LLC | $64.75 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $31.75 | 2021 | |
| Csl Behring | $30.95 | 2025 | Andembry |
| Kaleo, INC. | $24.46 | 2019 | |
| Circassia INC. | $18.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.